Reports Q4 revenue $316.96M, consensus $314.7M. “Bio-Techne (TECH) delivered a solid fourth quarter that was in-line with our expectations, despite ongoing market uncertainty,” said Kim Kelderman, president and CEO of Bio-Techne. “We achieved strong performance in our cell therapy and protein analysis instrumentation growth pillars, supported by a resilient pharma market. Our fiscal year 2025 results reflect the outstanding execution by our team and the meaningful impact our innovative solutions continue to deliver for customers, which include accelerating development timelines and driving scientific breakthroughs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne Divests Exosome Diagnostics to Boost Growth
- Bio-Techne to divest Exosome Diagnostics business to Mdxhealth
- Bio-Techne price target raised to $58 from $51 at Baird
- Promising Long-Term Growth for Bio-Techne Amidst Current Challenges: A Buy Recommendation by Kyle Boucher
- Bio-Techne resumed with an Overweight at Stephens